Apuli Maricel
Chief Accounting Officer
Apuli Maricel has filed 10 SEC Form 4 filings (11 transaction rows) across 1 company, with disclosures dating back to 2025. 10 of those filings fall inside the rolling window. Most recent filing: Aug 18, 2026.
On the most recent filing, Apuli Maricel is listed as Chief Accounting Officer at BridgeBio Pharma, Inc. Inside the rolling window, Apuli Maricel reported no open-market purchases and 5 open-market sales totaling $622K in BBIO. The largest disclosed transaction in the window is a sale of 2,000 BBIO shares on Jul 30, 2026, worth $160K.
Companies traded
Other insiders at BBIO
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$622K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Apuli Maricel made?
Apuli Maricel has filed 10 SEC Form 4 filings (11 transaction rows) across 1 company since 2025.
Which companies does Apuli Maricel trade?
Apuli Maricel has filed SEC Form 4 disclosures for 1 company, including BBIO.
When was Apuli Maricel's most recent SEC Form 4 filing?
Apuli Maricel's most recent SEC Form 4 filing on Tracefour is dated Aug 18, 2026.
What is Apuli Maricel's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Apuli Maricel is listed as Chief Accounting Officer.
What is Apuli Maricel's total buy and sell value in the current window?
Inside the rolling retention window, Apuli Maricel bought $0 and sold $622K based on SEC Form 4 filings.
What was Apuli Maricel's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 2,000 BBIO shares on 2026-07-30, worth $160K, per SEC Form 4 filings.